InVitae (NVTA) to Release Earnings on Monday
InVitae (NYSE:NVTA) is scheduled to be releasing its earnings data after the market closes on Monday, February 12th. Analysts expect InVitae to post earnings of ($0.55) per share for the quarter.
InVitae (NYSE:NVTA) opened at $6.24 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.61 and a current ratio of 2.61. The stock has a market cap of $326.67, a price-to-earnings ratio of -2.44 and a beta of 0.81. InVitae has a fifty-two week low of $5.91 and a fifty-two week high of $11.88.
A number of research firms have issued reports on NVTA. Zacks Investment Research downgraded shares of InVitae from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. Ladenburg Thalmann Financial Services began coverage on shares of InVitae in a report on Friday, January 5th. They set a “buy” rating and a $15.00 price objective on the stock. Leerink Swann cut their price objective on shares of InVitae from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. BidaskClub downgraded shares of InVitae from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Finally, Benchmark cut their price target on shares of InVitae from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 16th. Three equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. InVitae currently has a consensus rating of “Hold” and an average price target of $12.40.
ILLEGAL ACTIVITY WARNING: “InVitae (NVTA) to Release Earnings on Monday” was first posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/invitae-nvta-to-release-earnings-on-monday/1858344.html.
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.